1Dalen JE, Banas JS, Brooks HL, et al. Resolution rate of acute pulmonary embolism in man. N Engl J Med, 1969,280 : 1194-1199.
2Goldhaber SZ, Meyerovitz MF, Markis JE, et al . Thrombolytic therapy of acute pulmonary embolism: current status and future potential. J Am Coil Cardiol, 1987,10 (5 Suppl B) : 96 B-104 B.
3Goldhaber SZ,Kessler CM, Heit J,et al. Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet,1988, 2:293-298.
4Goldhabert SZ, Kessler CM, Heit JA, et al. Recombinant tissuetype plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial. J Am coll cardiol,1992,20: 24-30.
5Goldhaber SZ, Agnelli G, Levine MN . Reduced dose bolus alteplase vs conventional aheplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial. The Bolus Alteplase Pulmonary Embolism Group. Chest, 1994, 106:718-724.
6Jerjes-Sanchez C. Ramirez-Rivera A, de Lourdes Garcia ML,et al .Streptokinase and Heparin versus Heparin Alone in Massive Pulmonary Embolism: A Randomized Controlled Trial. J Thromb Thrombolysis, 1995,2 : 227 -229.
7European Society of Cardiology. Guidelines on diagnosis and management of acute pulmonary embolism. Task Force on Pulmonary Embolism, European Society of Cardiology. Eur Heart J, 2000, 21 :1301-1336.
8Daniels LB, Parker JA, Patel SR, et al . Relation of duration of symptoms with response to thrombolytic therapy in pulmonary embolism. Am J cardiol, 1997,80 : 184-188.
9Goldhaber SZ . Pulmonary Embolism. N Engl J Med, 1998,339:93-104.
6Wan S, Quinlan DJ,Agnelli G, et al. Thrombolysis compared with heparin for the initial treatment of pulmonary anbolism:ameta - analysis of the randomized controlled trials [ J ]. Circulation, 2004,110 ( 6 ) : 744-749.
